Ausgabe 2/2012
Inhalt (40 Artikel)
Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis
Yuting Wang, Chengpeng Zhang, Jianjun Liu, Gang Huang
Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b
Rupninder Sandhu, Ashley G. Rivenbark, William B. Coleman
Influence of stromal–epithelial interactions on breast cancer in vitro and in vivo
Shirley M. Potter, Roisin M. Dwyer, Marion C. Hartmann, Sonja Khan, Marie P. Boyle, Catherine E. Curran, Michael J. Kerin
Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?
K. H. Allison, P. L. Kandalaft, C. M. Sitlani, S. M. Dintzis, A. M. Gown
The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models
Hong Zhao, Kemi Cui, Fang Nie, Lulu Wang, Miriam B. Brandl, Guangxu Jin, Fuhai Li, Yong Mao, Zhong Xue, Angel Rodriguez, Jenny Chang, Stephen T. C. Wong
Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients
Nabila Chaher, Hugo Arias-Pulido, Nadija Terki, Clifford Qualls, Kamel Bouzid, Claire Verschraegen, Anne Marie Wallace, Melanie Royce
miRNA-34a is associated with docetaxel resistance in human breast cancer cells
L. Kastl, I. Brown, A. C. Schofield
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
In Hae Park, Jungsil Ro, Sohee Park, Hyeong-Seok Lim, Keun Seok Lee, Han Sung Kang, So-Youn Jung, Seeyeon Lee
The p160 ER co-regulators predict outcome in ER negative breast cancer
Melanie Spears, Steffi Oesterreich, Ilenia Migliaccio, Carolina Guiterrez, Susan Hilsenbeck, Mary Anne Quintayo, Johanna Pedraza, Alison F. Munro, Jeremy St. J. Thomas, Gill R. Kerr, Wilma J. L. Jack, Ian H. Kunkler, David A. Cameron, Udi Chetty, John M. S. Bartlett
Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer
Wenjie Jessie Lu, Zeruesenay Desta, David A. Flockhart
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Yunwei Han, Zhihao Yu, Shaoyan Wen, Bin Zhang, Xuchen Cao, Xin Wang
Compliance and persistence of endocrine adjuvant breast cancer therapy
Uwe Güth, Mary Elizabeth Myrick, Nerbil Kilic, Serenella Eppenberger-Castori, Seraina Margaretha Schmid
Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread
Andreas D. Hartkopf, Malgorzata Banys, Natalia Krawczyk, Annette Staebler, Sven Becker, Jürgen Hoffmann, Markus Hahn, Markus Wallwiener, Tanja Fehm
Sentinel lymph node analysis in breast cancer: contribution of one-step nucleic acid amplification (OSNA)
Florence Godey, Jean Leveque, Patrick Tas, Gwenola Gandon, Philippe Poree, Habiba Mesbah, Vincent Lavoue, Véronique Quillien, Cécile Bendavid Athias
Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first course
Hélène Kolesnikov-Gauthier, Laurence Vanlemmens, Marie-Christine Baranzelli, Philippe Vennin, Véronique Servent, Charles Fournier, Philippe Carpentier, Jacques Bonneterre
Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes
Jiyoung Kim, SeKyung Lee, SooYoun Bae, Min-Young Choi, Jeonghui Lee, Seung Pil Jung, Sangmin Kim, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial
Kathleen I. Pritchard, Alison Munro, Frances P. O’Malley, Dongsheng Tu, Xiao Li, Mark N. Levine, Lois Shepherd, Stephen Chia, John M. S. Bartlett
Are genetic and environmental components of variance in mammographic density measures that predict breast cancer risk independent of within-twin pair differences in body mass index?
Gillian S. Dite, Jennifer Stone, Anna M. Chiarelli, Graham G. Giles, Dallas R. English, Jennifer C. Cawson, John L. Hopper
Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women
Azadeh Stark, Robert Stapp, Aditya Raghunathan, Xiaowei Yan, H. Lester Kirchner, Jennifer Griggs, Lisa Newman, Dhananjay Chitale, Andrew Dick
Body mass index and risk of second primary breast cancer: The WECARE Study
Jennifer D. Brooks, Esther M. John, Lene Mellemkjær, Anne S. Reiner, Kathleen E. Malone, Charles F. Lynch, Jane C. Figueiredo, Robert W. Haile, Roy E. Shore, Jonine L. Bernstein, Leslie Bernstein
Aspirin use and breast cancer risk: a meta-analysis
Ting Luo, Hua-Mei Yan, Ping He, Yong Luo, Yuan-Fu Yang, Hong Zheng
Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients
Jennifer A. Ligibel, A. James O’Malley, Maxine Fisher, Gregory W. Daniel, Eric P. Winer, Nancy L. Keating
Changes in perceived attentional function in women following breast cancer surgery
Mei-Ling Chen, Christine Miaskowski, Li-Ni Liu, Shin-Cheh Chen
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer
Jennifer C. Livaudais, Dawn L. Hershman, Laurel Habel, Lawrence Kushi, Scarlett Lin Gomez, Christopher I. Li, Alfred I. Neugut, Louis Fehrenbacher, Beti Thompson, Gloria D. Coronado
Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy—Breast (FACT-B) in Asian breast cancer patients
Raymond Ng, Chun Fan Lee, Nan Soon Wong, Nan Luo, Yoon Sim Yap, Soo Kien Lo, Whay Kuang Chia, Alethea Yee, Lalit Krishna, Cynthia Goh, Yin Bun Cheung
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance
Valesca P. Retèl, Manuela A. Joore, Wim H. van Harten
Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project
Jeannette M. Beasley, Marilyn L. Kwan, Wendy Y. Chen, Erin K. Weltzien, Candyce H. Kroenke, Wei Lu, Sarah J. Nechuta, Lisa Cadmus-Bertram, Ruth E. Patterson, Barbara Sternfeld, Xiao-Ou Shu, John P. Pierce, Bette J. Caan
Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location
Johanna H. Vestjens, Maaike de Boer, Paul J. van Diest, Carolien H. van Deurzen, Jos A. van Dijck, George F. Borm, Eddy M. Adang, Peter Bult, Vivianne C. Tjan-Heijnen
Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy
R. Hein, S. Abbas, P. Seibold, R. Salazar, D. Flesch-Janys, J. Chang-Claude
Use of high technology imaging for surveillance of early stage breast cancer
K. S. Panageas, C. S. Sima, L. Liberman, D. Schrag
The relationship between twin births and maternal risk of breast cancer: a meta-analysis
Hye Sook Kim, Ok Hee Woo, Kyong Hwa Park, Sang Uk Woo, Dae Sik Yang, Ae-Ree Kim, Eun Sook Lee, Jae-Bok Lee, Yeul Hong Kim, Jun Suk Kim, Jae Hong Seo
Change in physical activity during active treatment in a prospective study of breast cancer survivors
Marilyn L. Kwan, Barbara Sternfeld, Isaac Joshua Ergas, Allegra W. Timperi, Janise M. Roh, Chi-Chen Hong, Charles P. Quesenberry, Lawrence H. Kushi
Variation between hospitals in surgical margins after first breast-conserving surgery in the Netherlands
Margriet van der Heiden-van der Loo, Linda de Munck, Otto Visser, Pieter J. Westenend, Thijs van Dalen, Marian B. Menke, Emiel J. Rutgers, Petra H. Peeters
The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms
Victoria K. Shanmugam, James McCloskey, Beth Elston, Sandra J. Allison, Jennifer Eng-Wong
Effect of simvastatin on the pharmacokinetics of anastrozole
Ting Bao, Amanda L. Blackford, Vered Stearns
Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity
Gabrielle Rocque, Adedayo Onitilo, Jessica Engel, Erica Pettke, Alice Boshoven, KyungMann Kim, Shailly Rishi, Bonnie Waack, Kari B. Wisinski, Amye Tevaarwerk, Mark E. Burkard
BRCA1 c.4987-3C>G is a pathogenic mutation
Rita D. Brandão, Kees E. P. van Roozendaal, Demis Tserpelis, Beppy Caanen, Encarna Gómez García, Marinus J. Blok
Erratum to: The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer
Gabrielle Colleran, Niall McInerney, Andrew Rowan, Ella Barclay, Angela M. Jones, Catherine Curran, Nicola Miller, Michael Kerin, Ian Tomlinson, Elinor Sawyer
Erratum to: Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort
N. M. McInerney, N. Miller, A. Rowan, G. Colleran, E. Barclay, C. Curran, M. J. Kerin, I. P. Tomlinson, E. Sawyer